Mohammed Ahmed Dahab

Dr. Mohammed Ahmed Dahab

Al Azhar University, Cairo, Al Qāhirah, Egypt
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2021 in Frontiers in Chemistry
Verified
Journal Article
Open access
PDF file
Ahmed A. Al-KarmalawyAhmed A. Al-Karmalawy
Ahmed A. Al-Karmalawy
Mohammed Ahmed DahabMohammed Ahmed Dahab
Mohammed Ahmed Dahab
Ahmed MetwalyAhmed Metwaly
Ahmed Metwaly
Sameh S. ElhadySameh S. Elhady
Sameh S. Elhady
Eslam B. ElkaeedEslam B. Elkaeed
Eslam B. Elkaeed
KDKhaled M. Darwish
Khaled M. Darwish
The rapid and global spread of a new human coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has produced an immediate urgency to discover promising targets for the treatment of COVID-19. Here, we consider drug repurposing as an attractive approach that can facilitate the drug discovery process by repurposing existing pharmaceuticals to treat illnesses other than their primary indications. We review current information concerning the global health issue of COVID-19 including promising approved drugs, e.g., human angiotensin-converting enzyme inhibitors (hACEIs). Besides, we describe computational approaches to be used in drug repurposing and highlight examples of in-silico studies of drug development efforts against SARS-CoV-2. Alacepril and lisinopril were found to interact with human angiotensin-converting enzyme 2 (hACE2), the host entranceway for SARS-CoV-2 spike protein, through exhibiting the most acceptable rmsd_refine values and the best binding affinity through forming a strong hydrogen bond with Asn90, which is assumed to be essential for the activity, as well as significant extra interactions with other receptor-binding residues. Furthermore, molecular dynamics (MD) simulations followed by calculation of the binding free energy were also carried out for the most promising two ligand-pocket complexes from docking studies (alacepril and lisinopril) to clarify some information on their thermodynamic and dynamic properties and confirm the docking results as well. These results we obtained probably provided an excellent lead candidate for the development of therapeutic drugs against COVID-19. Eventually, animal experiments and accurate clinical trials are needed to confirm the potential preventive and treatment effect of these compounds.

27 December 2021 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
Hazem ElkadyHazem Elkady
Hazem Elkady
AEAlaa Elwan
Alaa Elwan
HEHesham A. El-Mahdy
Hesham A. El-Mahdy
Ahmed S. DoghishAhmed S. Doghish
Ahmed S. Doghish
AIAhmed Ismail
Ahmed Ismail
MKMohamed Khalifa
Mohamed Khalifa
A new series of benzoxazole derivatives were designed and synthesised to have the main essential pharmacophoric features of VEGFR-2 inhibitors. Cytotoxic activities were evaluated for all derivatives against two human cancer cell lines, MCF-7 and HepG2. Also, the effect of the most cytotoxic derivatives on VEGFR-2 protein concentration was assessed by ELISA. Compounds 14o, 14l, and 14b showed the highest activities with VEGFR-2 protein concentrations of 586.3, 636.2, and 705.7 pg/ml, respectively. Additionally, the anti-angiogenic property of compound 14b against human umbilical vascular endothelial cell (HUVEC) was performed using a wound healing migration assay. Compound 14b reduced proliferation and migratory potential of HUVEC cells. Furthermore, compound 14b was subjected to further biological investigations including cell cycle and apoptosis analyses. Compound 14b arrested the HepG2 cell growth at the Pre-G1 phase and induced apoptosis by 16.52%, compared to 0.67% in the control (HepG2) cells. The effect of apoptosis was buttressed by a 4.8-fold increase in caspase-3 level compared to the control cells. Besides, different in silico docking studies were also performed to get better insights into the possible binding mode of the target compounds with VEGFR-2 active sites.

1 May 2021 in Bioorganic Chemistry
Verified
Journal Article
Closed access
NANawaf Abdulaziz Alsaif
Nawaf Abdulaziz Alsaif
Mohammed Ahmed DahabMohammed Ahmed Dahab
Mohammed Ahmed Dahab
MAMohammed M Alanazi
Mohammed M Alanazi
AOAhmad J Obaidullah
Ahmad J Obaidullah
AAAbdulrahman A Al-Mehizia
Abdulrahman A Al-Mehizia
Hazem ElkadyHazem Elkady
Hazem Elkady

1 July 2021 in Bioorganic Chemistry
Verified
Journal Article
Closed access
ARA. F. M. Motiur Rahman
A. F. M. Motiur Rahman
HMHazem A. Mahdy
Hazem A. Mahdy
NANawaf A. Alsaif
Nawaf A. Alsaif
AOAhmad J. Obaidullah
Ahmad J. Obaidullah
HAHamad Alkahtani
Hamad Alkahtani
Ibrahim. H. EissaIbrahim. H. Eissa
Ibrahim. H. Eissa

6 September 2021 in RSC Advances
Verified
Journal Article
Open access
PDF file
MAMohammed M. Alanazi
Mohammed M. Alanazi
Hazem ElkadyHazem Elkady
Hazem Elkady
NANawaf A. Alsaif
Nawaf A. Alsaif
AOAhmad Jomah Obaidullah
Ahmad Jomah Obaidullah
HAHamad Alkahtani
Hamad Alkahtani
Mohammed Ahmed DahabMohammed Ahmed Dahab
Mohammed Ahmed Dahab
A new series of 3-methylquinoxaline-based derivatives having the same essential pharmacophoric features as VEGFR-2 inhibitors have been synthesized and evaluated for their antiproliferative activities against two human cancer cell lines, MCF-7 and HepG-2. Compounds 15b and 17b demonstrated a significant antiproliferative effect with IC50 ranging from 2.3 to 5.8 μM. An enzymatic assay was carried out for all the tested candidates against VEGFR-2. Compound 17b was the most potent VEGFR-2 inhibitor (IC50 = 2.7 nM). Mechanistic investigation including cell cycle arrest and apoptosis was performed for compound 17b against HepG-2 cells, and the results revealed that 17b induced cell apoptosis and arrested cell cycle in the G2/M phase. Moreover, apoptosis analyses were conducted for compound 17b to evaluate its apoptotic potential. The results showed upregulation in caspase-3 and caspase-9 levels, and improving the Bax/Bcl-2 ratio by more than 10-fold. Docking studies were performed to determine the possible interaction with the VEGFR-2 active site. Further docking studies were carried out for compound 17b against cytochrome P450 to present such compounds as non-inhibitors. In silico ADMET, toxicity, and physico-chemical properties revealed that most of the synthesized members have acceptable values of drug-likeness. Finally, DFT studies were carried out to calculate the thermodynamic, molecular orbital and electrostatic potential properties.

1 July 2021 in Bioorganic Chemistry
Verified
Journal Article
Closed access
Ibrahim. H. EissaIbrahim. H. Eissa
Ibrahim. H. Eissa
Mohammed Ahmed DahabMohammed Ahmed Dahab
Mohammed Ahmed Dahab
MIMohamed K. Ibrahim
Mohamed K. Ibrahim
NANawaf A. Alsaif
Nawaf A. Alsaif
AAA.Z. Alanazi
A.Z. Alanazi
ABAndré M. Beauchemin
André M. Beauchemin